As of my last knowledge update, Walgreens Boots Alliance (WBA) has not yet released its Q2 2025 earnings report. However, based on historical trends and recent developments, here’s what to expect:
Expected Walgreens (WBA) Q2 2025 Earnings Overview
Earnings Release Date: Likely late March or early April 2025 (exact date TBA).
Previous Quarter (Q1 2025) Recap:
- Revenue: ~$36-37B (slight YoY decline).
- Adjusted EPS: ~0.80−0.90 (down due to lower pharmacy margins, opioid settlement impacts).
- Cost-cutting: $1B+ savings target from restructuring.
Key Focus Areas for Q2 2025:
- Retail & Pharmacy Performance
- Prescription volume trends amid GLP-1 drug boom (e.g., Ozempic, Wegovy).
- Consumer spending pressures in retail segments.
- Healthcare Services Growth
- Progress in VillageMD (primary care) and Walgreens Health initiatives.
- Potential downsizing/closures of underperforming clinics.
- Cost-Cutting & Profitability
- Updates on $1B+ savings plan (store optimizations, layoffs).
- Opioid litigation financial impacts.
- Guidance Revisions
- Will WBA maintain its full-year 2025 outlook? (Previously: ~3.20−3.50 adjusted EPS).
Market Expectations (Analyst Estimates)
- Revenue: ~$35-36B (flat to slight decline YoY).
- Adjusted EPS: ~0.85−1.00 (improving sequentially but down YoY).
Where to Watch?
- Official Source: WBA Investor Relations
- Earnings Call: CEO Tim Wentworth’s commentary on turnaround progress.
Need historical comparisons or stock impact analysis? Let me know! 📉📈
